AR002024A1 - Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. - Google Patents

Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Info

Publication number
AR002024A1
AR002024A1 ARP960101201A AR10120196A AR002024A1 AR 002024 A1 AR002024 A1 AR 002024A1 AR P960101201 A ARP960101201 A AR P960101201A AR 10120196 A AR10120196 A AR 10120196A AR 002024 A1 AR002024 A1 AR 002024A1
Authority
AR
Argentina
Prior art keywords
xaa
leu
ser
val
thr
Prior art date
Application number
ARP960101201A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR002024A1 publication Critical patent/AR002024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen proteínas anti-obesidad, que regulan el tejido adiposo cuando se administran al paciente, con lo cual es posible solucionar y/o prevenir losriesgos colaterales, debido a los estados de diabetes tipo II, cáncer o enfermedades cardiovasculares, asociados con la obesidad. Se trata de proteínasque tienen la secuencia (SEQ ID NO: 1) Val Pro Ile Xaa Lys Val Xaa Asp Asp Thr Lys Thr Leu Ile Lys ThrIle Val Thr Arg Ile Xaa Asp Ile Ser His XaaXaa Ser Val Ser Ser Lys Xaa Lys Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro IleLeu Thr Leu Ser Lys Xaa Asp Xaa Thr Leu Ala Val Tyr Xaa Xaa Ile Leu Thr Ser Xaa Pro Ser Arg Xaa Val Ile Xaa Ile Ser Xaa LeuGluc Xaa LeuArg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys His Lue Pro Xaa Ala Ser Gly Leu Glu Thr Leu Xaa Ser Leu Gly GlyVal Leu Glu Ala Ser Gly Tyr Ser Thr Val Val Ala Leu Ser Arg Leu Xaa Gly Ser Leu Asp Xaa Leu Xaa XaaLeu Asp Leu Ser Pro Gly CysLas referencias numéricas están ilustradas en la descripción y 1era. reinvidicación.
ARP960101201A 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas. AR002024A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38104895A 1995-01-31 1995-01-31
US38363895A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
AR002024A1 true AR002024A1 (es) 1998-01-07

Family

ID=27009220

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101201A AR002024A1 (es) 1995-01-31 1996-01-30 Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.

Country Status (10)

Country Link
EP (2) EP0725078A1 (es)
JP (1) JPH10513450A (es)
AR (1) AR002024A1 (es)
AU (1) AU4766196A (es)
CA (1) CA2211664A1 (es)
CO (1) CO4480036A1 (es)
PE (1) PE15297A1 (es)
TR (1) TR199600084A2 (es)
WO (2) WO1996023515A1 (es)
YU (1) YU5396A (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357096A (ja) * 1986-08-29 1988-03-11 工業技術院長 紐体切断装置
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
EP0736599A3 (en) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
IL118297A0 (en) * 1995-05-19 1996-09-12 Lilly Co Eli Obesity gene product
EP0744408A3 (en) * 1995-05-26 1997-01-02 Eli Lilly And Company Rhesus ob protein and DNA
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
AU7072896A (en) * 1995-09-19 1997-04-09 Eli Lilly And Company Dna encoding medicinal proteins
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
AU1406497A (en) * 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
EP0784982A3 (en) * 1996-01-19 1999-08-18 Eli Lilly And Company Obesity protein formulations
AU2243997A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
AU1705197A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
WO1997028824A1 (en) * 1996-02-06 1997-08-14 Eli Lilly And Company Obesity protein compounds and formulations thereof
HUP0000280A3 (en) * 1996-03-01 2002-09-30 Amgen Inc Thousand Oaks Canine ob protein compositions and methods
AU2548097A (en) * 1996-03-26 1997-10-17 Eli Lilly And Company Formulations of ob protein
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP0827750A3 (en) * 1996-08-23 2002-11-20 Eli Lilly And Company Obesity protein formulations
AU4582597A (en) * 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) * 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
AU5901698A (en) * 1996-12-20 1998-07-17 Eli Lilly And Company Protein crystals, their preparation and use
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
CA2217698A1 (en) * 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
CA2277282A1 (en) * 1997-01-17 1998-07-23 Eli Lilly And Company Obesity protein formulations
EP0991420A1 (en) * 1997-02-25 2000-04-12 Eli Lilly And Company Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands
US5965521A (en) * 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK3241558T3 (da) * 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
DE102012106607B4 (de) 2012-07-20 2024-04-04 Heliatek Gmbh Verfahren zur Versiegelung von Modulen mit optoelektronischen Bauelementen
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US20230212222A1 (en) * 2020-03-11 2023-07-06 Anygen Co., Ltd. Composition for anti-diabetes and anti-obesity comprising novel compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
FI931701A (fi) * 1992-04-17 1993-10-18 Sankyo Co Derivat av faktor som inhiberar fettbildning, framstaellning och anvaendning
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
PE15297A1 (es) 1997-05-22
EP0725079A1 (en) 1996-08-07
JPH10513450A (ja) 1998-12-22
WO1996023517A1 (en) 1996-08-08
CA2211664A1 (en) 1996-08-08
CO4480036A1 (es) 1997-07-09
WO1996023515A1 (en) 1996-08-08
TR199600084A2 (tr) 1996-08-21
YU5396A (sh) 1998-08-14
EP0725078A1 (en) 1996-08-07
AU4766196A (en) 1996-08-21

Similar Documents

Publication Publication Date Title
AR002024A1 (es) Proteinas utiles para el tratamiento de la obesidad, composiciones farmaceuticas que incluyen dichas proteinas para tratamientos anti-obesidady procedimiento para prepararlas.
TR200102729T2 (tr) Platelet yapışmasını bloke etme amaçlı protein
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
BR9908749A (pt) Composições e formulações de peptìdios e uso das mesmas
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
NO20053027L (no) Gastrinpreparater og formuleringer, og fremgangsmater for anvendelse og fremstilling.
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
AU4371799A (en) Lysine containing peptides for treatment of heart disease
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
WO1997015598A1 (en) Novel peptide
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
KR950702579A (ko) 트롬빈 억제제(thrombin inhibitors)
CA2266346A1 (en) Use of proteins as agents against autoimmune diseases
NO975565L (no) Benstimulerende faktor
Ferreira et al. Structure and effects of a kinin potentiating fraction F (AppF) isolated from Agkistrodon piscivorus piscivorus venom
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
AU2002365974A1 (en) Alpha-fetoprotein peptides and uses thereof
JP2005504516A (ja) ＨＡｂ１８Ｇ／ＣＤ１４７における拮抗剤及びその応用
BR0007816A (pt) Fator de estimulação óssea
IL115825A0 (en) Therapeutic protein
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor
US4840785A (en) Mammal intestinal hormone precursor and its use
TH34900A (th) โปรตีนยับยั้งความอ้วน
Mogard et al. Neurotensin-like immunoreactivity generated by pepsin from human plasma and gastric tissue